Cetuximab injection — Competitive Intelligence Brief

Cetuximab injection (Cetuximab injection) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: EGFR inhibitor monoclonal antibody. Area: Oncology.

phase 3 EGFR inhibitor monoclonal antibody EGFR (Epidermal Growth Factor Receptor) Oncology Small molecule

Target snapshot

Cetuximab injection (Cetuximab injection) — Shanghai Miracogen Inc.. Cetuximab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing growth signals and inducing cell death.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cetuximab injection TARGET	Cetuximab injection	Shanghai Miracogen Inc.	phase 3	EGFR inhibitor monoclonal antibody	EGFR (Epidermal Growth Factor Receptor)
Nimotuzumab Injection	Nimotuzumab Injection	Biotech Pharmaceutical Co., Ltd.	marketed	EGFR inhibitor monoclonal antibody	EGFR (Epidermal Growth Factor Receptor)
RT plus Nimotuzumab	RT plus Nimotuzumab	Sun Yat-sen University	phase 3	EGFR inhibitor monoclonal antibody	EGFR (Epidermal Growth Factor Receptor)
Nimotuzumab ( h-R3)	Nimotuzumab ( h-R3)	El Kendi Pharmaceuticals Manufacturing Company	phase 3	EGFR inhibitor monoclonal antibody	EGFR (Epidermal Growth Factor Receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (EGFR inhibitor monoclonal antibody class)

1. Biotech Pharmaceutical Co., Ltd. · 1 drug in this class
2. El Kendi Pharmaceuticals Manufacturing Company · 1 drug in this class
3. Shanghai Miracogen Inc. · 1 drug in this class
4. Sun Yat-sen University · 1 drug in this class